Get started
Author

Eri Takase

Observed name: E. Takase
ORCID: 0000-0001-9753-6896
Observed ORCID: 0000-0001-9753-6896
OpenAlex ID: A5004381938
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer
2019 · Hiroaki Akamatsu, Eriko Murakami, et al. · The Oncologist · 83
Impact of pre‐existing interstitial lung abnormal shadow on lung injury development and severity in patients of non‐small cell lung cancer treated with osimertinib
2022 · Ryota Shibaki, Yuichi Ozawa, et al. · Cancer Medicine · 15
A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer Patients
2023 · Eri Takase, Hiroaki Akamatsu, et al. · Journal of Pain and Symptom Management · 9
PDF
Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin‐based chemotherapy using short hydration: A randomized phase II trial
2024 · Eriko Murakami, Hiroaki Akamatsu, et al. · Cancer Medicine · 4
PDF
Treatment of refractory localized pulmonary nocardiosis caused by Nocardia mexicana with a combination of medication and surgery
2023 · Miwako Kogure, Eri Takase, et al. · Respirology Case Reports · 4
PDF
Sustained fever associated with immune checkpoint inhibitors may be a poor prognostic factor
2019 · Hiroki Ueda, Eriko Murakami, et al. · Annals of Oncology · 4
A multicenter, randomized, controlled, open-label trial to determine the optimal duration of steroid therapy for mild pneumonitis associated with immune checkpoint inhibitors.
2025 · Daichi Fujimoto, Mitsuhiro Abe, et al. · Journal of Clinical Oncology · 3
PDF
Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial
2026 · Daichi Fujimoto, Mitsuhiro Abe, et al. · American Journal of Respiratory and Critical Care Medicine · 2
Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN)
2026 · Yuhei Harutani, Hiroaki Akamatsu, et al. · Lung Cancer · 1
PDF
Comparison of the Immune Checkpoint Inhibitor‐Free Survival Between Patients Who Completed and Those Who Discontinued ICI for Non‐Small Cell Lung Cancer
2025 · Takahiro Nagai, Hiroaki Akamatsu, et al. · Thoracic Cancer · 1
PDF
A phase 2 study of CBDCA + PEM + pembrolizumab in elderly (≥75 yrs) patients with advanced non-Sq, NSCLC.
2025 · Hiroaki Akamatsu, Kazuhiro Negoro, et al. · Journal of Clinical Oncology · 1
Endobronchial Lipoma Treated With Endoscopic Microwave Coagulation to Relieve Atelectasis: The First Case Report
2025 · Eri Takase, Atsushi Washioka, et al. · Respirology Case Reports
PDF
P4.11E.22 Treatment-Free Survival in Advanced NSCLC Patients who Terminated Immune-Checkpoint Inhibitors.
2024 · T. Nagai, H. Akamatsu, et al. · Journal of Thoracic Oncology
PDF
Adjacent angle size correlates with diagnostic sensitivity of endobronchial ultrasonography with a guide sheath
2023 · Mai Kato, Daichi Fujimoto, et al. · Journal of Thoracic Disease
PDF
1271P A phase II study of high-flow nasal cannula as palliative care in advanced cancer patients
2022 · E. Takase, H. Akamatsu, et al. · Annals of Oncology
Works count: 15
Citation count: 127
H-index: 4
I10-index: 2
Year
Topic
Type